At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
aflibercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Federation Francophone de Cancerologie Digestive·interventional·Posted Mar 10, 2015·Updated Jul 10, 2024
In Brief
A Phase 2 clinical trial evaluating aflibercept and LV5FU2 for Colorectal Neoplasms. Completed, enrolled 117 participants across 58 sites.
Detailed Summary
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMay 2015
Primary CompletionJun 2021
TodayJul 2026
First PostedMar 10, 2015
Enrollment StartMay 1, 2015
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 11.3 years ago
Interventions
afliberceptdrug
LV5FU2drug